Videos

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Medical experts discuss interchangeability designation requirements for biosimilars.

Here are the top 5 biosimilar articles for the week of November 13, 2023.

In partnership with The Center for Biosimilars®, the International Generic and Biosimilar Association hosted a live webinar, where panelists gathered from around the globe to discuss benefits as well as major barriers and accessibility challenges associated with oncology biosimilars worldwide.

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.

Here are the top 5 biosimilar articles for the week of November 6, 2023.

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications.

Experts compare approaches to prescribing biosimilars over reference drugs.

Here are the top 5 biosimilar articles for the week of October 30, 2023.

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Here are the top 5 biosimilar articles for the week of October 23, 2023.

Panelists explore opportunities for biosimilars to manage inflammatory conditions.

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses why providers need to be wary when deciding whether patients with Crohn disease should switch from Humira (reference adalimumab) to an adalimumab biosimilar.

Here are the top 5 biosimilar articles for the week of October 16, 2023.

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, shares why his study comparing the safety and efficacy of Cyltezo, an adalimumab biosimilar, with the originator (Humira) matters for patients with gastroenertology conditions.

Here are the top 5 biosimilar articles for the week of October 9, 2023.

Pfizer Global Biosimilars Commercial Lead, Roman Irsiegler, gives his thoughts on why a sustainable biosimilars market is critical for the healthcare industry, and what stakeholders can do to achieve it.

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, explained the initial experience gastroenterologists have had with anti–tumor necrosis factor biosimilars and how new adalimumab biosimilars will impact the space.

Here are the top 5 biosimilar articles for the week of October 2, 2023.

Here are the top 5 biosimilar articles for the week of September 25, 2023.

Here are the top 5 biosimilar articles for the week of September 18, 2023.

Here are the top 5 biosimilar articles for the week of September 11, 2023.

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, explains the value of interchangeability in the adalimumab space and predicts whether interchangeable biosimilars will become leaders in adoption.

Here are the top 5 biosimilar articles for the week of September 4, 2023.

Here are the top 5 biosimilar articles for the week of August 28, 2023.